Dr. Reddy’s Laboratories Ltd. has announced the launch of Linaclotide, a first-in-class guanylate cyclase-C (GC-C) agonist, for adults suffering from chronic idiopathic constipation (CIC) in India.
Marketed under the brand name Colozo®, Linaclotide will be available in 72 mcg and 145 mcg strengths, making Dr. Reddy’s the first pharmaceutical company to secure regulatory approval for this therapy in India.
Linaclotide is already USFDA-approved for chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) in adults, and functional constipation (FC) in children aged 6–17 years. It works as a highly selective GC-C receptor agonist in the intestine, improving bowel function.
In India, Linaclotide (Colozo®) has been approved specifically for the treatment of CIC in adults.
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: “The launch of Colozo® marks a significant step in our gastrointestinal segment in India and adds to our list of novel and first-in-class drugs after the launch of BixiBat® in India last year. Colozo® is a differentiated, USFDA-approved solution for Chronic Constipation. Backed by robust clinical evidence and promising outcomes, Colozo® represents a breakthrough in addressing unmet needs of patients and enhancing their quality of life. With Colozo®, we continue to strengthen our commitment to deliver advanced therapies that meaningfully improve everyday patient care, in keeping with our goal to serve 1.5 bn patients by 2030.”